HOME > BUSINESS
BUSINESS
- Takeda Nabs Top Japanese Analyst for Global IR Team
April 16, 2019
- Mitsubishi Tanabe ALS Drug Accepted for Review in China
April 16, 2019
- Daiichi Sankyo’s Lyrica Contender Tarlige Now Available
April 16, 2019
- Bayer Japan Ethical Drug Sales Slip 1% in 2018
April 15, 2019
- AstraZeneca Japan on Track for 4 Launches in 2019, Dependence on Crestor Fades
April 15, 2019
- Amgen Looks to Debut 3 Oncology Drugs in Next 3 Years: Global Commercial Chief
April 12, 2019
- Sanofi, Yakult Close Down Zaltrap Copromotion
April 12, 2019
- Sumitomo Dainippon to Soon Decide What to Do with ADHD Med Dasotraline after Setback
April 12, 2019
- Sumitomo Dainippon Shoots for Sales of 600 Billion Yen in FY2022, Revving Up “Post-Latuda” Pipeline Acquisition
April 12, 2019
- Mitsubishi Tanabe Joins Shonan iPark; 1st Pharma Company without Financial Ties to Takeda
April 12, 2019
- Shionogi Licenses Constipation Med to BioDelivery Sciences for Commercialization in US
April 12, 2019
- Teva Takeda Plans to Roll Out One AG Annually: CEO
April 11, 2019
- Kyowa to Skip May Listing for Enbrel Biosimilar, Codeveloper YL Biologics to Move Ahead
April 11, 2019
- Nearly 300 Kyowa Kirin Staffers Offer to Leave under Redundancy Program
April 11, 2019
- Hisamitsu Sales Down 3.4% on Price Cuts, Generic Erosion
April 11, 2019
- Diabetes Drug Imeglimin Hits Primary Goal in Japan PIII: Sumitomo, Poxel
April 10, 2019
- Xofluza Most Promoted Drug in January: Anterio
April 10, 2019
- Drug Makers Scratching Heads to Meet Daily Rep Report Requirements for New Detailing Guidelines
April 10, 2019
- Medipal’s Subsidiary to Distribute Stemirac in Japan
April 9, 2019
- Oncolys, Chugai Ink 50 Billion Yen Licensing Pact for Telomelysin
April 9, 2019
ページ
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
